Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival

Clinical Transplantation

Volumn 10, Issue 6 I, 1996, Pages 538-541

  Hariharan, S ^a,c   Alexander, J W ^b   Schroeder, T J ^b   First, M R ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Acute rejection; Rejection severity; Renal transplant outcome

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; CADAVER KIDNEY; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ACTUARIAL ANALYSIS; ACUTE DISEASE; ADULT; ANTI-INFLAMMATORY AGENTS; BIOPSY; CADAVER; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MUROMONAB-CD3; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030452048     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. MERION RM, WHITE DJG, THIRU S, EVANS DB, CALNE RY. Cyclosporine: Five years experience in cadaveric renal transplantation. N Engl J Med 1984: 310: 148.
2. EUROPEAN MULTICENTER TRIAL GROUP. Cyclosporine in cadaveric renal transplantation: One year follow-up of a multicenter trial. Lancet 1983: 2: 986.
3. THE CANADIAN MULTICENTER TRANSPLANT STUDY GROUP, A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. N Engl J Med 1986: 314: 1219.
4. CALNE RY. Cyclosporine in cadaveric renal transplantation: 5 year follow-up of a multicenter trial. Lancet 1987 2: 506.
5. KRAMER NC, PETERS TG, ROHR MS, THACKER LR, VAUGHN WK. Beneficial effect of cyclosporine on renal transplantation. Transplantation 1990: 49: 343.
6. BASADONNA GP, MATAS AJ, GILLINGHAM KJ, et al. Early versus late acute renal allograft rejection: Impact on chronic rejection. Transplantation 1993: 55: 993.
7. THIEL G, BOCK A, SPONDLIN M, et al. Long-term benefits and risks of cyclosporin A (Sandimmune) - An analysis at 10 years. Transpl Proc 1994: 26: 2493.
8. TESI RJ, HENRY ML, ELKHAMMAS EA, FERGUSON RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transpl 1993: 7: 345.
9. DUNN J, GOLDEN D, VANBUREN CT, LEWIS RM, LAWEN J, KAHAN BD. Causes of graft loss beyond two years in the cyclosporine era. Transplantation 1990: 49: 49.
10. CECKA JM, CHO YW, TERASAKI PI. Analyses of the UNOS Scientific Renal Transplant Registry at three years - early events affecting transplant success. Transplantation 1992: 53: 59.
11. CECKA JM, TERASAKI PI. Early rejection episodes. In: TERASAKI ed. Clinical Transplants 1989. Los Angeles: UCLA Tissue Typing Laboratory, 1990:425.
12. BURKE JF, PIRSCH JD, RAMOS EL, et al. Long-term efficacy and safety of cyclosporine in renal transplant recipients. N Engl J Med 1994: 331: 358.
13. SOLEZ K, AXELSEN RA, BENEDIKSON H, et al. International standardization of criteria of the histological diagnosis of renal allograft rejection: The Banff's working classification of kidney transplant pathology. Kid Int 1993: 44: 411.
14. SCHROEDER TJ, WEISS MA, SMITH RD, STEPHENS GW, CAREY M, FIRST MR. The efficacy of OKT3 in vascular rejection. Transplantation 1991:51:312.
15. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457.
16. FIRST MR. Renal allograft survival after 1 and 10 years: Comparison between pre-cyclosporine and cyclosporine data. Nephrol Dial Transpl 1993: 9: 90.
17. HARIHARAN S, ALEXANDER JW, SCHROEDER TJ, FIRST MR. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era. Clin Transpl 1996: 10: 186.